다발성 골수종에서 Lenalidomide 치료 후 발생한 이차성 원발 종양

• Published in: The Korean journal of medicine Vol. 86; no. 3; pp. 353 - 356
• Main Authors: 이혜정, Hye Jung Lee, 김은석, Eun Seok Kim, 이호진, Ho Jin Lee, 강상현, Sang Hyeon Kang, 박인철, In Chul Park, 이지현, Ji Hyun Lee, 김성현, Sung Hyun Kim
• Format: Journal Article
• Language: Korean
• Published: 대한내과학회 01.03.2014
• Subjects: Breast cancer; Lenalidomide; Multiple myeloma; Secondary primary malignancy
• ISSN: 1738-9364

Lenalidomide, an orally administered immune-modulating drug, has several mechanisms of action against multiple myeloma (MM). However, the mechanisms of action of immune-modulating drugs are not understood completely. Lenalidomide maintenance therapy prolongs the time to progression and increases the overall survival in patients with MM. However, secondary primary malignancy (SPM) has been noted as a serious adverse event in patients with MM treated with lenalidomide. Lenalidomide treatment is not covered by insurance. Consequently, physicians have little experience with the adverse events of lenalidomide treatment in patients with MM. Here, we describe a case of breast cancer after lenalidomide treatment for MM. To our knowledge, this is the first report of a lenalidomide-associated SPM in Korea. The risk factors associated with lenalidomide-associated SPM should be considered carefully when implementing chemotherapy regimens in patients with MM.